Sab, there was never a chance of Rett approval because the trials failed and no regulatory application (NDA, MAA, etc) was ever made. The small trials showed that trials could be run that would likely succeed, but that is all.
The AD trial, data, and analysis show that approval of blarcasemine for AD is likely warranted. The results were compelling, The follow-on OLE results were compelling, too. The MAA was filed, it was accepted, it progressed pass CS1 all the way to the 180 mark. Blarcasemine is on the doorstep of approval and millions of people will benefit if this happens. And thousands shareholders will also benefit.
The negativity at this point makes little sense. Yes, things can always go sideways - but as long as the company is not burying its head in the sand about some non-public issues, then I think EMA will approve.
Market Data 
Markets 
AI
